MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. [electronic resource]
Producer: 20071011Description: 3955-61 p. digitalISSN:- 0264-410X
- Adjuvants, Immunologic -- adverse effects
- Adolescent
- Adult
- Chronic Disease -- therapy
- Double-Blind Method
- Female
- Humans
- Influenza A Virus, H3N2 Subtype -- immunology
- Influenza B virus -- immunology
- Influenza Vaccines -- adverse effects
- Influenza, Human -- complications
- Male
- Middle Aged
- Polysorbates -- adverse effects
- Risk Factors
- Squalene -- adverse effects
- Vaccines, Subunit -- adverse effects
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.